NCT01535027View on ClinicalTrials.gov

Combined Administration of Teripapartide and Antiresorptive Agents in Postmenopausal Osteoporosis

PHASE4CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Osteoporosis
Interventions
DRUG

teriparatide

teriparatide 20 ug/day, sc.

DRUG

teriparatide and raloxifene

teriparatide 20 ug/day sc. raloxifene 60mg oral daily

DRUG

teriparatide and alendronate

teriparatide 20 ug/day sc. alendronate 70mg oral weekly

Trial Locations (1)

1060

Medical University of Vienna, Vienna

All Listed Sponsors
lead

Medical University of Vienna

OTHER

NCT01535027 - Combined Administration of Teripapartide and Antiresorptive Agents in Postmenopausal Osteoporosis | Biotech Hunter | Biotech Hunter